Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Opevesostat - Orion

Next Previous
Drug Profile

Opevesostat - Orion

Alternative Names: MK-5684; ODM-208

Latest Information Update: 03 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orion
  • Developer Merck Sharp & Dohme; Orion
  • Class Antineoplastics; Ethers; Isoindoles; Piperidines; Pyrones; Small molecules; Sulfones
  • Mechanism of Action Cholesterol side chain cleavage enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 20 May 2025 Merck Sharp & Dohme plans a phase II Basket trial in Solid tumours, HER2- breast cancer, ovarian cancer, and endometrial cancer (Second-line therapy or greater, Late-stage diseases, Metastatic disease, Combination Therapy, First line therapy) in July 2025 (NCT06979596) (EudraCT2024-519563-18) (EudraCT2024-519563-18)
  • 13 May 2025 Merck Sharp & Dohme completes a phase I pharmacokinetic trial (In volunteers) (PO) (NCT06633419)
  • 09 May 2025 Merck Sharp & Dohme initiates a phase I pharmacokinetic trial in Healthy volunteers in USA (PO, Tablet) (NCT06860243)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top